INSOMNIA is the #8 most commonly reported adverse reaction for ATOMOXETINE HYDROCHLORIDE, manufactured by Eli Lilly and Company. There are 1,221 FDA adverse event reports linking ATOMOXETINE HYDROCHLORIDE to INSOMNIA. This represents approximately 1.9% of all 63,960 adverse event reports for this drug.
Patients taking ATOMOXETINE HYDROCHLORIDE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
INSOMNIA1,221 of 63,960 reports
INSOMNIA is a less commonly reported adverse event for ATOMOXETINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
Other Side Effects of ATOMOXETINE HYDROCHLORIDE
In addition to insomnia, the following adverse reactions have been reported for ATOMOXETINE HYDROCHLORIDE:
INSOMNIA has been reported as an adverse event in 1,221 FDA reports for ATOMOXETINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is INSOMNIA with ATOMOXETINE HYDROCHLORIDE?
INSOMNIA accounts for approximately 1.9% of all adverse event reports for ATOMOXETINE HYDROCHLORIDE, making it a notable side effect.
What should I do if I experience INSOMNIA while taking ATOMOXETINE HYDROCHLORIDE?
If you experience insomnia while taking ATOMOXETINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.